Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Arix Bioscience PLC (ARIX) Artios initiates Phase 2 study of Pol Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BR...

Related Keywords

Germany ,New York ,United States ,Tennessee ,Netherlands ,United Kingdom ,Texas ,Cambridge ,Cambridgeshire ,Babraham ,London ,City Of ,Ibrahim Khalil ,Timothy Yap ,Sarah Macleod ,Arix Bioscience ,Artios Pharma ,Niall Martin ,Nature Communications ,Sarah Cannon Research Institute At Tennessee Oncology ,Artios Press ,Novartis ,Artios Pharma Limited ,Merck Kga ,Crick Institute ,Netherlands Cancer Institute ,Babraham Research Campus In Cambridge ,Cancer Research Technology ,Cancer Research Horizons ,University Of Texas Md Anderson Cancer Center ,Powerscourt Group ,Institute For Applied Cancer Science ,Institute Of Cancer Research ,Cancer Research United Kingdom ,Merck Kgaa ,Gynecologic Cancer Research Program ,Pol Inhibitor ,Chief Executive Officer ,Breast Cancer ,Sarah Cannon Research Institute ,Tennessee Oncology ,Associate Professor ,Investigational Cancer Therapeutics ,Medical Director ,Applied Cancer Science ,Cancer Research ,Babraham Research Campus ,New York City ,